A Double-Blind, Placebo-Controlled Trial of Modafinil for Cocaine Dependence
The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Abstract
Despite years of active research, there are still no approved medications for the treatment of cocaine dependence. Modafinil is a glutamate-enhancing agent that blunts cocaine euphoria under controlled conditions, and the current study assessed whether modafinil would improve clinical outcome in cocaine-dependent patients receiving standardized psychosocial treatment. This was a randomized, double-blind, placebo-controlled trial conducted at a university outpatient center (from 2002 to 2003) on a consecutive sample of 62 (predominantly African American) cocaine-dependent patients (aged 25-63) free of significant medical and psychiatric conditions. After screening, eligible patients were randomized to a single morning dose of modafinil (400 mg), or matching placebo tablets, for 8 weeks while receiving manual-guided, twice-weekly cognitive behavioral therapy. The primary efficacy measure was cocaine abstinence based on urine benzoylecgonine levels. Secondary measures were craving, cocaine withdrawal, retention, and adverse events. Modafinil-treated patients provided significantly more BE-negative urine samples (p=0.03) over the 8-week trial when compared to placebos, and were more likely to achieve a protracted period (> or =3 weeks) of cocaine abstinence (p=0.05). There were no serious adverse events, and none of the patients failed to complete the study as a result of adverse events. This study provides preliminary evidence, which should be confirmed by a larger study, that modafinil improves clinical outcome when combined with psychosocial treatment for cocaine dependence.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients with severe chronic health concerns tend to have a slower response to treatment with fewer days abstinent compared to patients without them.225”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [225]
In the citing paper
“A randomized placebo-controlled trial of modafinil (400mg/d) for CUD indicated significantly lower use compared to placebo, but no significant differences in craving or withdrawal (56), while a larger subsequent trial showed no differences in cocaine use, craving, withdrawal, retention, or abstinence even when accounting for dosage (57).”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as [56]
In the citing paper
“Significantly greater abstinence compared to placebo, but no significant differences in craving or withdrawal.”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as Dackis et al., 2005
In the citing paper
“Significantly greater abstinence compared to placebo, but no significant differences in craving or withdrawal.”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as Dackis et al., 2005
In the citing paper
“Significantly greater abstinence compared to placebo, but no significant differences in craving or withdrawal.”
From Clinical management of psychostimulant withdrawal: review of the evidence (2023) · cites this paper as Dackis et al., 2005
Citations
Cites
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Development of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
(2001) · Statistics for Psychologists · doi:10.4324/9781410605542-11 · Cited by 6,877
The measurement of pessimism: the hopelessness scale
Beck, A. T., Weissman, A., Lester, D., & Trexler, L. (1974) · Journal of Consulting and Clinical Psychology · doi:10.1037/h0037562 · Cited by 5,494 · cited 3×
“…were assessed with the Addiction Severity Index (ASI) (McLellan et al, 1992), Hamilton Anxiety Scale (Ham A) (Hamilton, 1969), and Hamilton Depression Scale (Ham D) (Hamilton, 1967), Beck Depression Inventory (BDI) (Beck et al, 1974), and the Symptom Checklist 90 Revised (SCL90) (Derogatis, 1977).”
MethodThe fifth edition of the addiction severity index
McLellan, A. T., Kushner, H., Metzger, D., Peters, R., Smith, I., Grissom, G., Pettinati, H., & Argeriou, M. (1992) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(92)90062-s · Cited by 4,222
Self-citationSobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110
Diggle, P. J., Heagerty, P. J., Liang, K.-Y., & Zeger, S. L. (2002) · doi:10.1093/oso/9780198524847.001.0001 · Cited by 3,384
Sheehan, D., Lecrubier, Y., Harnett Sheehan, K., Janavs, J., Weiller, E., Keskiner, A., Schinka, J., Knapp, E., Sheehan, M., & Dunbar, G. (1997) · European Psychiatry · doi:10.1016/s0924-9338(97)83297-x · Cited by 2,149
[Drug addiction and drug abuse].
Feuerlein, W. (1969) · PubMed · Cited by 1,415
Research works printed but not linked: 4
- First MB, Spitzer RL, Gibbon M, Williams JBW (1996). Structured Clinical Interview for DSM-IV Axis I Disorders—Subject Edition (SCID-I/P, Version 2.0). Biometrics Research Department New York State Psychiatric Institute: New York.
- Kadden R, Carroll K, Donovan D, Cooney N, Monti P, Abrams D et al (1992). Cognitive-Behavioral Coping Skills Therapy Manual. US Government Printing Office: Washington, DC.
- Malcolm RJ, Donovan JL, DeVane CL, Elkashef A, Chiang N, Mojsiak J (2002). Influence of Modafinil, 400 or 800 mg/day on Subjective Effects of Intravenous Cocaine in Non-treatment Seeking Volunteers. College on Problems of Drug Dependence: Quebec City.
- Somoza E, Dyrenforth S, Goldsmith J, Mezinskis J, Cohen M (1995). In search of a Universal Drug Craving Scale. Annual Meeting of the American Psychiatric Association: Miami, FL.
Cited by
Items 201–300 of 391
New medications for the treatment of cocaine dependence.
Kampman, K. M. (2005) · PubMed · Cited by 30
Self-citationInhibitory Control and Drug Abuse Prevention: From Research to Translation
Bardo, M. T., Fishbein, D. H., & Milich, R. S. (2011) · Springer eBooks · doi:10.1007/978-1-4419-1268-8 · Cited by 70
Karila, L., Leroy, C., Dubol, M., Trichard, C., Mabondo, A., Marill, C., Dubois, A., Bordas, N., Martinot, J.-L., Reynaud, M., et al. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.28 · Cited by 27
Euphorigenic and Abusive Properties of Modafinil
KRUSZEWSKI, S. P. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.3.549 · Cited by 22
Nuijten, M., Blanken, P., van den Brink, W., & Hendriks, V. M. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-135 · Cited by 25
“In addition, modafinil showed effectiveness in terms of duration of abstinence in the treatment of cocaine dependence in two randomised controlled trials [34,35], and in the reduction of craving in cocaine dependent patients without comorbid alcohol dependence [36].”
BackgroundResultModafinil and nicotine interactions in abstinent smokers
Sofuoglu, M., Waters, A. J., & Mooney, M. E. (2007) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.878 · Cited by 23
“In a recent clinical trial with cocainedependent outpatients, modafinil, compared to placebo, reduced cocaine use behavior (Dackis et al., 2005).”
BackgroundPettinati, H. M., Kampman, K. M., Lynch, K. G., Dundon, W. D., Mahoney, E. M., Wierzbicki, M. R., & O’Brien, C. P. (2014) · American Journal on Addictions · doi:10.1111/j.1521-0391.2014.12146.x · Cited by 19
“Eight weeks has been found in previous trials to be a trial duration that enables sufficient retention of cocaine‐addicted patients to discern a medication versus placebo difference.(22)”
Self-citationThe safety of modafinil in combination with oral ∆9-tetrahydrocannabinol in humans
Sugarman, D. E., Poling, J. C., & Sofuoglu, M. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.12.013 · Cited by 24
“Modafinil is currently being examined for the treatment of cocaine and methamphetamine addiction (Dackis et al., 2005a; Hart et al., 2008; Morgan et al., 2010; Shearer et al., 2009a).”
BackgroundInfluentialSmart, K. A., Desmond, R. C., Poulos, C. X., & Zack, M. H. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.05.015 · Cited by 23
“Initial evidence supports modafinil’s clinical efficacy and low abuse liability in cocaine dependence (Dackis et al., 2005).”
BackgroundDoes Modafinil Produce Euphoria?
O’Brien, C. P., Dackis, C. A., & Kampman, K. M. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.6.1109 · Cited by 20
Self-citationHigh Resolution Mapping of Modafinil Induced Changes in Glutamate Level in Rat Brain
Haris, M., Singh, A. K., Cai, K., Nath, K., Verma, G., Nanga, R. P. R., Hariharan, H., Detre, J. A., Epperson, N., & Reddy, R. D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103154 · Cited by 20
Attention Deficit Hyperactivity Disorder and Substance Use Disorders
Bukstein, O. G. (2011) · Current topics in behavioral neurosciences · doi:10.1007/7854_2011_148 · Cited by 23
R-Modafinil Attenuates Nicotine-Taking and Nicotine-Seeking Behavior in Alcohol-Preferring Rats
Wang, X.-F., Bi, G., He, Y., Yang, H.-J., Gao, J., Bakare, O. M., Slack, R. D., Gardner, E. L., Xi, Z., & Newman, A. H. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.24 · Cited by 19
“In contrast, several recent clinical trials failed to confirm the therapeutic efficacy of (±)-MOD in treatment of cocaine (Dackis et al, 2012) or methamphetamine dependence (Anderson et al, 2012; De La Garza et al, 2010; Lee et al, 2013).”
ResultNovel C-1 Substituted Cocaine Analogs Unlike Cocaine or Benztropine
Reith, M. E. A., Ali, S., Hashim, A., Sheikh, I. S., Theddu, N., Gaddiraju, N. V., Mehrotra, S., Schmitt, K. C., Murray, T. F., Sershen, H. W., et al. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.193771 · Cited by 18
Novel Pharmacological Approaches to Drug Abuse Treatment
Edens, E. L., Massa, A. A., & Petrakis, I. L. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_29 · Cited by 23
“The first double-blind, placebocontrolled, out-patient RCT showed the modafanil-treated group had significantly higher rates of negative urine screens compared to placebo; however, no differences were found in treatment retention, cocaine craving, and withdrawal measures (Dackis et al. 2005).”
BackgroundExpert opinion on pharmacotherapy of narcolepsy
Zaharna, M., Dimitriu, A., & Guilleminault, C. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.484021 · Cited by 18
“In the USA, protriptyline is the most commonly used TCA for treatment of cataplexy and is essentially a norepinephrine reuptake inhibitor [45].”
BackgroundWuo‐Silva, R., Fukushiro, D. F., Hollais, A. W., Santos-Baldaia, R., Mári-Kawamoto, E., Berro, L. F., Yokoyama, T. S., Lopes-Silva, L. B., Bizerra, C. S., Procópio‐Souza, R., et al. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00420 · Cited by 18
“In contrast, in a more recent study, Dackis et al. (2012) showed that modafinil failed to decrease the positive urine samples for cocaine in drug addicts.”
ResultDeSantis, S. M., Bandyopadhyay, D., Back, S. E., & Brady, K. T. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.07.008 · Cited by 19
Substance Abuse and Depression
Renner, J. A., Baxter, J., Suzuki, J., & Ciraulo, D. A. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-435-7_6 · Cited by 18
Vansickel, A. R., Fillmorex, M. T., Hays, L. R., & Rush, C. R. (2008) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990802013565 · Cited by 18
“These medications have been tested as pharmacotherapies in outpatient clinical trials and appear to be effective in reducing drug use (11, 13).”
BackgroundJoos, L., Goudriaan, A. E., Schmaal, L., van den Brink, W., Sabbe, B. G., & Dom, G. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113503505 · Cited by 19
“Our sample size was based on a previous reported trial with modafinil for cocaine dependence (Dackis et al., 2005).”
MethodSchmitz, J. M., Stotts, A. L., Vujanovic, A. A., Yoon, J. H., Webber, H. E., Lane, S. D., Weaver, M. F., Vincent, J. N., Suchting, R., & Green, C. E. (2024) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.111078 · Cited by 20
Li, Y.-Q., Wang, X.-Y., Zhai, H., Zheng, Y.-Q., Zhang, X., Kosten, T. A., & Lü, L. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1169-9 · Cited by 17
Foltin, R. W., Haney, M., Bedi, G., & Evans, S. M. (2016) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2016.08.009 · Cited by 16
“Dackis et al. (2012) failed to find efficacy for modafinil (400 mg/d) for cocaine use disorders, yet there was the possibility that sex mediated the effect as males receiving modafinil tended (p <0.06) to achieve greater abstinence than females.”
BackgroundInfluentialKeighron, J. D., Giancola, J. B., Shaffer, R. J., DeMarco, E. M., Coggiano, M. A., Slack, R. D., Newman, A. H., & Tanda, G. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.14256 · Cited by 18
“Although in a larger clinical trial, the overall results were less convincing (Dackis et al., 2012), a subpopulation of patients”
ResultLiu, Y. P., Tung, C. S., Lin, Y., & Chuang, C. H. (2010) · Psychopharmacology · doi:10.1007/s00213-010-2019-0 · Cited by 20
“…MOD cannot offer any benefits when the individual is already exhausted due to the lack of sleep, strengthens the potential of using MOD as a replacement treatment in patients dependent on other psychostimulant drugs (Dackis et al. 2005; Karila et al. 2008; Martínez-Raga et al. 2008; Shearer 2008).”
BackgroundNew medications for the treatment of cocaine dependence.
Kampman, K. M. (2009) · PubMed · Cited by 18
Self-citationBiotechnology and the Treatment of Addictive Disorders: New Opportunities
Elkashef, A. M., Biswas, J., Acri, J. B., & Vocci, F. J. (2007) · BioDrugs · doi:10.2165/00063030-200721040-00006 · Cited by 18
Modafinil, an atypical CNS stimulant?
Hersey, M., & Tanda, G. (2023) · Advances in pharmacology · doi:10.1016/bs.apha.2023.10.006 · Cited by 23
Sex differences in dopamine binding and modafinil conditioned place preference in mice
Bernardi, R. E., Broccoli, L., Spanagel, R., & Hansson, A. C. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.08.016 · Cited by 16
“Furthermore, modafinil decreased craving (Anderson et al., 2009) and increased abstinence duration (Dackis et al., 2005) in cocaine-dependent individuals relative to placebo.”
BackgroundOpen‐label pilot study of lisdexamfetamine for cocaine use disorder
Mariani, J. J., Choi, C. J., Pavlicová, M., Mahony, A. L., Brooks, D. J., Grabowski, J. G., & LEVIN, F. R. (2021) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2021.1885677 · Cited by 16
The effects of oral d-amphetamine on impulsivity in smoked and intranasal cocaine users
Collins, S. L., & Evans, S. M. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.04.013 · Cited by 15
“…have suggested that other agonist-like medications, such as modafinil and methylphenidate, may have utility as cocaine treatment medications (e.g., Dackis et al., 2003, 2005; Grabowski et al., 2001; Mariani and Levin, 2012; Martínez-Raga et al., 2008; Vansickel et al., 2008; Winhusen et al.,…”
BackgroundRuger, J. P., Abdallah, A. B., Luekens, C., & Cottler, L. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033594 · Cited by 14
Rahimi, O., Cao, J., Lam, J., Childers, S. R., Rais, R., Porrino, L. J., Newman, A. H., & Nader, M. A. (2022) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001363 · Cited by 15
“Early clinical trials reported that modafinil successfully reduced cocaine intake and prevented relapse (Dackis et al., 2005; Hart et al., 2008; Kampman et al., 2015).”
BackgroundThe mu/kappa agonist nalbuphine attenuates sensitization to the behavioral effects of cocaine
Smith, M. A., Cole, K. T., Iordanou, J. C., Kerns, D. C., Newsom, P. C., Peitz, G. W., & Schmidt, K. T. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2012.12.026 · Cited by 14
“For instance, clinical trials examining the efficacy of agonist substitution therapies have reported positive findings with amphetamine and other stimulants (Grabowski et al., 2004; Dackis et al., 2005; Mooney et al., 2009); however, amphetamine-like drugs carry significant abuse liability and produce sensitization an…”
A cost‐effectiveness analysis of modafinil therapy for psychostimulant dependence
Shearer, J., Shanahan, M., Darke, S. G., Rodgers, C., van Beek, I., McKetin, R., & Mattick, R. P. (2010) · Drug and Alcohol Review · doi:10.1111/j.1465-3362.2009.00148.x · Cited by 15
Quisenberry, A. J., Prisinzano, T. E., & Baker, L. E. (2013) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0031832 · Cited by 14
“Despite some promising preliminary findings regarding modafinil as a potential treatment for psychostimulant dependence (Dackis, Kampman, Lynch, Pettinati, & O’Brien, 2005; Hart, Haney, Vosburg, Rubin, & Foltin, 2008), clinicians may want to proceed with caution until further research determines…”
Therapeutic options and challenges for substances of abuse
Gardner, T. J., & Kosten, T. R. (2007) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2007.9.4/tgardner · Cited by 14
Modafinil treatment of amphetamine abuse in adult ADHD
Mann, N. S., & Bitsios, P. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108091258 · Cited by 15
Pharmacotherapy for Stimulant-Related Disorders
Haile, C. N., & Kosten, T. R. (2013) · Current Psychiatry Reports · doi:10.1007/s11920-013-0415-y · Cited by 13
Modafinil inhibits KCa3.1 currents and muscle contraction via a cAMP-dependent mechanism
Choi, S., Kim, M. Y., Joo, K. Y., Park, S., Kim, J. A., Jung, J., Oh, S., & Suh, S. H. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.02.009 · Cited by 15
Moosavi, S. M., Charati, J. Y., & Amini, F. (2019) · PubMed Central · doi:10.22122/ahj.v11i3.219 · Cited by 14
Social Influences on Nicotine-Related Behaviors
Piña, J. A., Namba, M. D., Leyrer‐Jackson, J. M., Cabrera-Brown, G., & Gipson, C. D. (2018) · International review of neurobiology · doi:10.1016/bs.irn.2018.07.001 · Cited by 18
Adjunctive use of modafinil in bipolar patients: just another stimulant or not?
Shelton, R. C., & Reddy, R. (2008) · Current Psychiatry Reports · doi:10.1007/s11920-008-0082-6 · Cited by 11
Galvin, E. M., BOESJES, H., Hol, J. W., Ubben, J. F. H., Klein, J., & Verbrugge, S. J. C. (2010) · Acta Anaesthesiologica Scandinavica · doi:10.1111/j.1399-6576.2009.02093.x · Cited by 11
New treatments for cocaine abuse
Dackis, C. A. (2005) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2005.04.003 · Cited by 13
Self-citationPharmacothérapies actuelles et immunothérapie dans l’addiction à la cocaïne
Karila, L., Weinstein, A. M., Benyamina, A., Coscas, S., Leroy, C., Noble, F., Lowenstein, W., Aubin, H., Lépine, J., & Reynaud, M. (2008) · La Presse Médicale · doi:10.1016/j.lpm.2007.08.015 · Cited by 12
“Les patients sous modafinil avaient de meilleurs résultats en termes d’abstinence que les patients sous placebo, aucun effet secondaire spécifique n’a été relevé [40].”
BackgroundDowling, G., Kavanagh, P. V., Talbot, B. N., O’Brien, J. E., Hessman, G., McLaughlin, G., Twamley, B., & Brandt, S. D. (2016) · Drug Testing and Analysis · doi:10.1002/dta.2142 · Cited by 11
Quisenberry, A. J., Prisinzano, T. E., & Baker, L. E. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.07.011 · Cited by 10
STDs Among Illicit Drug Users in the United States: The Need for Interventions
Semaan, S., C., P. D. C. D. J. D., & Malow, R. M. (2007) · Springer eBooks · doi:10.1007/978-0-387-48740-3_17 · Cited by 13
New horizons: sustained release morphine as agonist treatment
WOODY, G. E. (2005) · Addiction · doi:10.1111/j.1360-0443.2005.01286.x · Cited by 10
Attention-Deficit/Hyperactivity Disorder, Binge Eating, and Obesity
Cortese, S., Isnard, P., Bernardina, B. D., & Mouren, M. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0624h · Cited by 10
Allen, M. I., Rahimi, O., Johnson, B., Cao, J., Newman, A. H., & Nader, M. A. (2024) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.124.002356 · Cited by 9
Leidl, D. M., Takhar, P., & Li, H. (2023) · International Journal of Mental Health Nursing · doi:10.1111/inm.13144 · Cited by 10
Pramipexole Increases Go Timeouts but Not No-go Errors in Healthy Volunteers
Yang, X. Q., Glizer, D., Vo, A., Seergobin, K. N., & MacDonald, P. A. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00523 · Cited by 14
“…medication, has been shown to increase abstinence in cocaine users (Martínez-Raga et al., 2008; Anderson et al., 2009), to reduce laboratory cocaine self-administration and cocaine dependence in double-blind, placebo-controlled clinical studies (Dackis et al., 2005; Hart et al., 2008).”
BackgroundBeyond ADHD and narcolepsy: psychostimulants in general psychiatry
Ng, B., & O’Brien, A. (2009) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.107.004879 · Cited by 9
“One RCT reported benefits of modafinil on abstinence rates in cocaine dependence (Dackis 2005), whereas another (Grabowski 1997) found no benefits with methylphenidate.”
Le point sur l’addiction à la cocaïne et au crack
Charles‐Nicolas, A., Lacoste, J., & Ballon, N. (2009) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2009.06.016 · Cited by 9
“Agoniste glutamatergique, elle a montré son efficacité dans deux études randomisées [10,11], en association à une thérapie comportementale et cognitive, en aidant les patients à rester plus longtemps abstinents que le placebo et en réduisant les effets positifs induits par la prise de cocaïne.”
BackgroundBehavioral and Cross Sensitization after Repeated Exposure to Modafinil and Apomorphine in Rats
Chang, S. T. (2010) · The Chinese Journal of Physiology · doi:10.4077/cjp.2010.amk067 · Cited by 9
“001), as well as significant treatment-by-time point interactions (LM: F(6,84) = 6.”
BackgroundInfluentialMedications for the treatment of cocaine addiction: Emerging candidates
Herman, B. H., Elkashef, A. M., & Vocci, F. J. (2005) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2005.05.014 · Cited by 12
Bruce, R. D., Smith-Rohrberg, D., & Altice, F. L. (2007) · Springer eBooks · doi:10.1007/978-0-387-71695-4_23 · Cited by 9
Modafinil does not reduce cocaine use in methadone-maintained individuals
DeVito, E. E., Poling, J. C., Babuscio, T. A., Nich, C., Carroll, K. M., & Sofuoglu, M. (2022) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2022.100032 · Cited by 7
Carpenter, K. M., Choi, C. J., Basaraba, C. N., Pavlicová, M., Brooks, D. J., Brezing, C., Bisaga, A. M., Nunes, E. V., Mariani, J. J., & LEVIN, F. R. (2024) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000676 · Cited by 7
Schizophrenia Symptoms Remain Stable During Decreases From 2 Antipsychotics to Aripiprazole
Salzman, C., Rosenberg, J., & Feldman, J. J. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0624a · Cited by 7
Modafinil for Bipolar Depression with Comorbid Methamphetamine Abuse
Camacho, A., Ng, B., & Frye, M. A. (2010) · American Journal on Addictions · doi:10.1111/j.1521-0391.2009.00024.x · Cited by 7
Regier, P. S., Kampman, K. M., & Childress, A. R. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_303 · Cited by 7
Self-citationNew pharmacotherapies for treating the neurobiology of alcohol and drug addiction.
Pettinati, H. M., & Rabinowitz, A. R. (2006) · PubMed Central · Cited by 7
Self-citationSoler‐Cedeño, O., Galaj, E., Klein, B., Cao, J., Bi, G., Newman, A. H., & Xi, Z. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03391-7 · Cited by 6
Perspectives Emerging From Neuroscience on How People Become Addicted and What to Do About It
Littrell, J. L. (2010) · Journal of Social Work Practice in the Addictions · doi:10.1080/1533256x.2010.498741 · Cited by 9
Therapeutic challenges of attention-deficit hyperactivity disorder with substance use disorders
Bukstein, O. G. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.4.541 · Cited by 7
Dopaminergic mediation of the discriminative stimulus functions of modafinil in rats
Quisenberry, A. J., & Baker, L. E. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4065-0 · Cited by 5
“However, clinical studies of modafinil for the treatment of cocaine (Dackis et al. 2005; Schmitz et al. 2012; Anderson et al. 2009), amphetamine (Mann and Bitsios 2008), or methamphetamine (Shearer et al.”
BackgroundResultInfluentialBiological and psychological interventions: Trends in substance use disorders intervention research
Wessell, R., & Edwards, C. E. (2010) · Addictive Behaviors · doi:10.1016/j.addbeh.2010.07.009 · Cited by 6
Burrows, B. T., Watterson, L. R., Johnson, M. A., & Olive, M. F. (2015) · Journal of Drug and Alcohol Research · doi:10.4303/jdar/235958 · Cited by 5
Rambert, F. A., Hermant, J. F., & Schweizer, D. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00300-x · Cited by 7
Neue Entwicklungen in der Pharmakotherapie der Kokainabhängigkeit
Wiesbeck, G. A., & Dürsteler‐MacFarland, K. M. (2006) · Der Nervenarzt · doi:10.1007/s00115-005-2044-0 · Cited by 5
Rocha, B. A. G., Bergman, J., Comer, S. D., Haney, M., & Spealman, R. D. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373861-5.00027-8 · Cited by 7
Modafinil: Mischaracterization
Kruszewski, S. P., & Klotz, S. G. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0624b · Cited by 5
Vincristine-induced unilateral ptosis with serendipitous response to modafinil: Figure 1
Revannasiddaiah, S., & Bhattacharyya, T. (2011) · BMJ Case Reports · doi:10.1136/bcr.07.2010.3178 · Cited by 4
The effects of amphetamine, butorphanol, and their combination on cocaine self-administration
Smith, M. A., Pennock, M., Pitts, E. G., Walker, K. L., & Lang, K. C. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.08.012 · Cited by 4
Pharmacotherapy for Cocaine Use Disorders
Quednow, B. B., Engeli, E., & Herdener, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_457 · Cited by 4
Haney, M., Rubin, E., Denson, R. K., & Foltin, R. W. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108554 · Cited by 4
“In clinical trials, modafinil appears more efficacious in reducing cocaine use in men than in women (Dackis et al., 2012).”
BackgroundIvanov, I., Newcorn, J. H., Morton, K., & Tricamo, M. (2011) · Springer eBooks · doi:10.1007/978-1-4419-1268-8_7 · Cited by 4
Modafinil: an anti-relapse medication
Tahsili‐Fahadan, P., Malcolm, R. J., & Aston‐Jones, G. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.123 · Cited by 4
“More importantly, modafinil decreases cocaine use and relapse rates in cocaine addicts (Dackis et al, 2005; Hart et al, 2008).”
BackgroundMcCarty, D. (2010) · Nature and Science of Sleep · doi:10.2147/nss.s6680 · Cited by 5
“Of interest, these findings may help explain some recent observations regarding the potential benefit of modafinil in the treatment of cocaine addiction.(45) More importantly, in total, these data suggest a mechanism for modafinil that involves dopaminergic signaling, and which may be, in fact, quite similar to that o…”
Ron, P. D., Dremier, S., Winlow, P., Jenkins, A., Hanon, É., & da Costa, A. N. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.01.010 · Cited by 4
“(Hart et al., 2008; Vosburg et al., 2010; Dackis et al., 2012, O'Brien, 2012).”
Psychische Störungen und Verhaltensstörungen durch psychotrope Substanzen
Fehr, C., Szegedi, A., Scherbaum, N., Davids, E., Gastpar, M., Leweke, F. M., Hoyer, C., Gouzoulis‐Mayfrank, E., & Lorscheider, M. (2008) · Springer eBooks · doi:10.1007/978-3-540-68748-1_40 · Cited by 4
Pharmacological Treatment of Substance Abuse Disorders
Raby, W. N., Mariani, J. J., LEVIN, F. R., & Nunes, E. V. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch113 · Cited by 4
Schmitt, K. C., & Reith, M. E. A. (2012) · PLoS ONE · doi:10.1371/annotation/ba711a7c-13fb-4d18-89a8-28dcc68fcd04 · Cited by 4
Ruger, J. P., Abdallah, A. B., Luekens, C., & Cottler, L. B. (2012) · PLoS ONE · doi:10.1371/annotation/d9d8b547-8154-48a1-b527-d0c51285ed3c · Cited by 4
Clinical aspects of cocaine and methamphetamine dependence
Washton, A. M. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511782107.016 · Cited by 3
The Efficacy of Transactional Analysis as a Community-Based Intervention for Substance Use Disorder
Williams, I. C., & Glarino, G. G. (2023) · Transactional Analysis Journal · doi:10.1080/03621537.2023.2213970 · Cited by 5
“The Cronbach’s alpha coefficient was .91 (Dackis et al., 2004).”
MethodAngarita, G. A., Canavan, S. V., Hodges, S. E., & MORGAN, P. T. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800212-4.00021-2 · Cited by 4
Dossett, E. C., Land, A. J., Gitlin, M. J., & Frye, M. A. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0624e · Cited by 3
Modafinil-Cocaine Interactions: Clinical Implications
O’Brien, C. P. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.07.004 · Cited by 3
Self-citationPharmacological manipulation of impulsivity: A randomized controlled trial
Kulendran, M., Wingfield, L. R., Sugden, C., Darzi, A. W., & Vlaev, I. (2015) · Personality and Individual Differences · doi:10.1016/j.paid.2015.11.025 · Cited by 3
Bohnenberger, K., & Krenzelok, E. P. (2014) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 3
Kadric, S., Möhler, H., Kallioniemi, O., & Altmann, K. H. (2019) · World Journal of Neuroscience · doi:10.4236/wjns.2019.93008 · Cited by 3
“Although proven pharmacotherapies are available for alcohol and heroin dependence none exist for cocaine dependence despite two decades of clinical trials primarily involving antidepressants, anticonvulsants, and dopaminergic medications [3] [4] [5].”
BackgroundTesting the Use of a Social Networking App for American Indians Recovering from Addiction
Guenzel, N., McChargue, D. E., & Dai, H. D. (2021) · Journal of Technology in Behavioral Science · doi:10.1007/s41347-021-00196-5 · Cited by 3
Medications for Substance Use Disorders
Daley, D. C., & Douaihy, A. B. (2019) · Oxford University Press eBooks · doi:10.1093/med-psych/9780190926717.003.0006 · Cited by 3
Taking addiction research into the clinic
(2005) · Nature Neuroscience · doi:10.1038/nn1105-1413 · Cited by 3
Flindall, I. R., Leff, D. R., Goodship, J., Sugden, C., & Darzi, A. W. (2015) · Surgery · doi:10.1016/j.surg.2015.09.017 · Cited by 2
Metadata
- Authors
- Dackis, C. A., Kampman, K. M., Lynch, K. G., Pettinati, H. M., & O'Brien, C. P.
- Affiliations
- University of Pennsylvania (US)
- Corresponding author
- Dackis, Charles A
- Venue
- Neuropsychopharmacology
- Published
- 2004-11-03
- Volume
- 30
- Issue
- 1
- Pages
- 205-211
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W1966136869
- Cited by
- 391
- References
- 44
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 9 · 2023: 8 · 2022: 9 · 2021: 13 · 2020: 2 · 2019: 10 · 2018: 6 · 2017: 8 · 2016: 21 · 2015: 17 · 2014: 21 · 2013: 21 · 2012: 26
- FWCI
- 19.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p60da005186-25)
- National Institute on Drug Abuse (DA P60-05186, DA P50-12756, P50DA012756)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- modafinil, cocaine dependence, cocaine abstinence, cognitive behavioral therapy, psychosocial interventions, cocaine craving, cocaine withdrawal, medication-assisted treatment, African American patients
- MeSH terms
- Modafinil, Adult, Central Nervous System Stimulants, Benzhydryl Compounds, Double-Blind Method, Female, Humans, Male, Middle Aged, Patient Compliance, Psychiatric Status Rating Scales, Substance Withdrawal Syndrome, Treatment Outcome, Sample Size, Cocaine-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.